Jump to content

Marc Feldmann

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Rcb1 (talk | contribs) at 16:04, 27 April 2022 (deleted category as already in sub-category). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Sir Marc Feldmann
Born (1944-12-02) 2 December 1944 (age 79)
Lvov
CitizenshipAustralia/United Kingdom
Alma mater
Known fordiscovery of anti-TNF therapy for rheumatoid arthritis and other autoimmune diseases
Awards
Scientific career
FieldsImmunology
InstitutionsKennedy Institute of Rheumatology, Imperial College London, University of Oxford
Doctoral studentsAshok Venkitaraman[1]

Sir Marc Feldmann, AC FAA FRS FRCP FRCPath FMedSci (born 2 December 1944), is an Australian-educated British immunologist. He is a professor at the University of Oxford and a Senior Research Fellow at Somerville College, Oxford.[2]

Biography

Feldmann was born 2 December 1944 in Lvov to a Jewish family who managed to get to France immediately postwar.[3][4][5] He emigrated from France to Australia at age eight.[5] After graduating with an MBBS degree from the University of Melbourne in 1967, he earned a Ph.D. in Immunology at the Walter and Eliza Hall Institute of Medical Research in 1972 with Sir Gustav Nossal.[3][4]

He moved to London in the 1970s, working first with Avrion Mitchison at the Imperial Cancer Research Fund's Tumour Immunology Unit; in 1985 he moved to the Charing Cross Sunley Research Centre and the Kennedy Institute of Rheumatology (which joined with the Faculty of Medicine at Imperial College in 2000; in August 2011 the Institute transferred to the University of Oxford.[4]

Research

In the 1980s he published an hypothesis for the mechanism of induction of autoimmune diseases, highlighting the role of cytokines.[6] This model was validated in experiments with thyroid disease tissue. From 1984 he collaborated with Ravinder N. Maini at the Kennedy Institute of Rheumatology to study disease mechanism in rheumatoid arthritis, an autoimmune disease affecting 1% of the population.[7]

Feldmann's group demonstrated that diseased joints have far more pro-inflammatory cytokines than normal, and identified one of these, tumour necrosis factor alpha, (abbreviated TNFα) as the key.[8]

Blocking TNFα reduced levels of the other pro-inflammatory cytokines in test-tube models of arthritis,[9] and this provided the rationale for testing TNF blockade in rheumatoid arthritis patients which had failed all existing treatment.

The first of a series of successful clinical trials was performed in 1992 at Charing Cross Hospital, using the antibody infliximab from Centocor, a biotech now part of Johnson and Johnson.[citation needed]

The success led to other companies joining the race to market. By 1998,[10] etanercept (Enbrel)[11] was approved for treatment in the US, and by 1999, infliximab (Remicade) was also approved; there have been multiple additional approved anti-TNF drugs, and they have become standard therapy cfor stopping the inflammatory and tissue-destructive pathways of rheumatoid arthritis and other autoimmune diseases including Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriasis and psoriatic arthritis.[7][12]

Prizes and fellowships

In 2000, Feldmann and Maini were awarded the Crafoord Prize;[13][14] in 2003, the Albert Lasker Award for Clinical Medical Research;[15] in 2002, the Cameron Prize for Therapeutics of the University of Edinburgh; in 2008, the Dr. Paul Janssen Award for Biomedical Research;[16] in 2010, the Ernst Schering Prize in Germany; in 2014, the Canada Gairdner International Award. Feldmann was also awarded the John Curtin Medal of the Australian National University in 2007. In 2020 he received the Tang Prize in Biopharmaceutical Science.[17]

Feldmann is Fellow of the Royal College of Physicians and of the Royal College of Pathologists. He was elected a Fellow of several national Academies, the Academy of Medical Sciences, the Royal Society of London and is a Corresponding Member of Australian Academy of Science, and a Foreign Member of the National Academy of Sciences, USA. He was knighted in the 2010 Queen's Birthday Honours.[18]

In 2012 he delivered the Croonian Lecture to the Royal College of Physicians on anti-cytokine therapy.[19]

References

  1. ^ Venkitaraman, Ashok Ramakrishnan (1989). "The regulation of MHC class 2 gene expression by tumours of the B lymphocyte lineage" (Document). hdl:10044/1/47696. {{cite document}}: Cite document requires |publisher= (help)
  2. ^ "Sir Marc Feldmann". Somerville College, Oxford. Retrieved 1 April 2020.
  3. ^ a b Feldmann, M. (2009) Translating molecular insights in autoimmunity into effective therapy. Annu. Rev. Immunol. 27: 1-27.
  4. ^ a b c "Feldmann, Marc". ISIHighlyCited.com. Retrieved 21 November 2008.
  5. ^ a b "Marc Feldmann" (PDF). Johnson & Johnson Pharmaceutical Services. Retrieved 21 November 2008.
  6. ^ Bottazzo, G.F., Pujol-Borrell, R., Hanafusa, T. and Feldmann, M. (1983) Hypothesis: Role of aberrant HLA-DR expression and antigen presentation in the induction of endocrine autoimmunity. Lancet ii: 1115-1119.
  7. ^ a b "Professor Marc Feldmann wins top lifetime achievement award". News-Medical.Net. 24 April 2007. Retrieved 21 November 2008.
  8. ^ Feldmann, M., Brennan, F.M. and Maini, R.N. (1996) Role of cytokines in rheumatoid arthritis. Annu Rev. Immunol. 14: 397-440.
  9. ^ Brennan, F.M., Chantry, D., Jackson, A., Maini, R.N. and Feldmann, M. (1989) Inhibitory effect of TNF-alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet ii: 244-247.
  10. ^ Elliott, M.J., Maini, R.N., Feldmann, M., Long-Fox, A., Charles, P., Katsikis, P., Brennan, F.M., Walker, J., Bijl, H., Ghrayeb, J. and Woody, J. (1993) Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to TNF-alpha. Arth. Rheum 36: 1681-90.
  11. ^ Elliott, M.J., Maini, R.N., Feldmann, M., Kalden, J.R., Antoni, C., Smolen, J.S., Leeb, B., Breedveld, F.C., Macfarlane, J.D., Bijl, H. and Woody, J.N. (1994) Randomised double-blind comparison of a chimeric monoclonal antibody to tumour necrosis factor-alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344: 1105-1110.
  12. ^ Feldmann, M. and Maini, R.N. (2001) Anti-TNF-alpha therapy of rheumatoid arthritis: What have we learned? Annual Review Immunology 19: 163-196.
  13. ^ "Crafoord Prize 2000". The Royal Swedish Academy of Sciences. Retrieved 23 November 2008. [dead link‍]
  14. ^ "Crafoord Prize 2000 Press Release". The Royal Swedish Academy of Sciences. Retrieved 24 November 2008. [dead link‍]
  15. ^ "The 2003 Albert Lasker Clinical Medical Research Award". Lasker Foundation. Retrieved 21 November 2008.
  16. ^ "Professors Marc Feldmann and Sir Ravinder Maini Named Winners of the 2008 Dr. Paul Janssen Award for Biomedical Research". Johnson & Johnson Pharmaceutical Services. Archived from the original on 29 January 2010. Retrieved 23 November 2008.
  17. ^ Tang Prize 2020
  18. ^ "No. 59446". The London Gazette (Supplement). 12 June 2010. p. 1.
  19. ^ "Royal College of Physicians- Events Diary". Royal College of Physicians. Archived from the original on 23 December 2012. Retrieved 7 September 2012.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Marc_Feldmann&oldid=1084961923"